Showing results (21-30 of 58) with videos related to
Sort By:
Pageof 6
Molecular Metabolism|February 4, 2018
Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled studySandra Hummel, Andreas Beyerlein, Markus Pfirrmann, et al.Leukemia|July 28, 2022
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemiaLioba Schönfeld, Jenny Rinke, Anna Hinze, et al.Leukemia & Lymphoma|July 17, 2020
No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study groupThoralf Lange, Christian Niederwieser, Arthur Gil, et al.BMJ Open|November 10, 2021
Supplementation with <i>Bifidobacterium longum</i> subspecies <i>infantis</i> EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocolAnette-Gabriele Ziegler, Stefanie Arnolds, Annika Kölln, et al.Contemporary Clinical Trials Communications|February 7, 2025
Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocolSandra Hummel, Alexandra Käßl, Stefanie Arnolds, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemiaRüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz, et al.Lancet (London, England)|November 14, 2025
Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trialAnette-Gabriele Ziegler, Peter Achenbach, Andreas Weiß, et al.Blood|August 21, 2013
Comprehensive mutational profiling in advanced systemic mastocytosisJuliana Schwaab, Susanne Schnittger, Karl Sotlar, et al.American Journal of Hematology|August 29, 2019
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobinMichael Lauseker, Katharina Bachl, Anna Turkina, et al.Diabetologia|January 30, 2021
Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trialRobin Assfalg, Jan Knoop, Kristi L Hoffman, et al.Pageof 6